(MENAFN- IMARC Group)
According to the latest report by IMARC Group, titled “Multiple Myeloma Drugs Market: Global industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032,” provides an extensive analysis of the industry, including multiple myeloma drugs market report . The report also covers competitor and regional analysis and the latest advancements in the global market.
The global multiple myeloma drugs market size reached US$ 22.3 Billion in 2023 . Looking forward, IMARC Group expects the market to reach US$ 35.5 Billion by 2032 , exhibiting a growth rate (CAGR) of 5.2% during 2024-2032 .
Multiple Myeloma Drugs Market Overview:
Multiple myeloma, also called Kahler's disease, represents a form of blood cancer that generally affects the plasma cells and is caused by specific genetic abnormalities. Some of the common multiple myeloma drugs usually include corticosteroids, chemotherapeutic agents, and immunomodulatory agents. These pharmaceutical drugs help in preventing hypercalcemia, bone fracture, spinal cord compression, anemia, etc., promoting bone healing, minimizing the need for chemotherapy, etc. The chemotherapeutic agents include several anthracycline antibiotics and alkylating agents, such as doxorubicin, melphalan, vincristine, liposomal doxorubicin, etc. The targeted therapy drugs also include proteasome inhibitors, such as bortezomib, and other compounds, including prednisone, dexamethasone, thalidomide, etc.
Get Sample Copy of Report at – https://www.imarcgroup.com/multiple-myeloma-drugs-market/requestsample
Global Multiple Myeloma Drugs Industry Trends:
The introduction of advanced technologies in the healthcare sector, along with the rising prevalence of hematological cancer, is primarily driving the multiple myeloma drugs market. Additionally, the growing need for the treatment of this disease that involves medications to enhance the efficiency of radiation therapies, chemotherapies, stem cell transplants, and platelet transfusion is further bolstering the market growth. Besides this, the elevating consumer awareness towards the benefits of using biological therapy drugs to identify and attack myeloma cells is acting as another significant growth-inducing factor. Moreover, the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma is positively influencing the global market. Apart from this, they are used to catalyze antitumor responses and facilitate the delivery of macromolecular agents into the bone marrow, which is also stimulating the market growth. Furthermore, the inflating healthcare expenditures of individuals and extensive investments medical sciences are anticipated to fuel the multiple myeloma drugs market over the forecasted period.
Competitive Landscape With Key Players:
Amgen Inc. Bristol Myers Squibb Daiichi Sankyo Co., Ltd. Sanofi-Aventis Groupe (Genzyme Corporation) Johnson & Johnson Services, Inc. Merck & Co., Inc. Novartis International AG Pfizer Inc. PHARMA MAR, S.A. Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Ltd
Key Market Segmentation:
Breakup by Therapy:
Targeted Therapy Biologic Therapy Chemotherapy Others
Breakup by Drug Type:
Immunomodulatory Drugs Proteasome Inhibitors Histone Deacetylase Inhibitors Monoclonal Antibody Drugs Steroids Others
Breakup by End-User:
Breakup by Distribution Channel:
Hospital Pharmacies Retail Pharmacies Online Pharmacies Others
Breakup by Region:
North America (United States, Canada) Europe (Germany, France, United Kingdom, Italy, Spain, Others) Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others) Latin America (Brazil, Mexico, Others) Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key Highlights of the Report:
Market Performance Market Outlook Porter's Five Forces Analysis Market Drivers and Success Factors SWOT Analysis Value Chain Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Who we are:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
Contact us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email:
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
MENAFN28022024004122016232ID1107911083
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.